Loading cancer entity…
Loading cancer entity…
Clinical trials
298 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04708470 | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 |
| clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04432597 | HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers | completed | Phase 1 / Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06233331 | Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV | not yet recruiting | Phase 1 | 9 | Emory UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT02698293 | PDT Plus Vitamin D3 for Anal Dysplasia | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04287868 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07668284 | COQ10 and Vitamin E for Off-Target Radiation Toxicity | not yet recruiting | Phase 1 / Phase 2 | 200 | University of NebraskaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03386500 | Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer | active not recruiting | Phase 1 / Phase 2 | 24 | University of NebraskaOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05334004 | Lopinavir/Ritonavir in PLWH With High-Grade AIN | recruiting | Phase 1 | 21 | University of Wisconsin, MadisonOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 79 | National Cancer Institute (NCI)NIH | 2 | Jan 21, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT04328740 | Phase 1 Study of Oral TP-1454 | completed | Phase 1 | 31 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT02199236 | Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management | completed | Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06544720 | SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas | recruiting | Phase 1 | 18 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT05578820 | Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid | completed | Phase 1 | 21 | Gene Surgery LLCINDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05518201 | Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old | completed | Phase 1 | 90 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06358053 | CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | not yet recruiting | Phase 1 | 24 | Corregene Biotechnology Co., LtdINDUSTRY | 0 | Apr 10, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05952947 | HRYZ-T101 Injection for HPV18 Positive Solid Tumor | recruiting | Phase 1 | 32 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT04672980 | RTX-321 Monotherapy in Patients With HPV 16+ Tumors | terminated | Phase 1 | 9 | Rubius TherapeuticsINDUSTRY | 1 | Dec 8, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05122221 | CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers | unknown | Phase 1 | 12 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | Jun 28, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT01324141 | Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer | terminated | Phase 1 | 6 | National Cancer Institute (NCI)NIH | 1 | Nov 23, 2021 | clinicaltrials |
| NCT03100045 | Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)(ART-AIN) | completed | Phase 1 | 18 | Johns Hopkins UniversityOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000764 | Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection. | completed | Phase 1 | 98 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Oct 28, 2021 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT01621217 | Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0(NOAC8) | completed | Phase 1 | 21 | Lund University HospitalOTHER | 2 | Feb 28, 2020 | clinicaltrials |
| NCT01671488 | A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer(276) | terminated | Phase 1 / Phase 2 | 11 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03677960 | Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection | terminated | Phase 1 | 6 | Antiva BiosciencesINDUSTRY | 2 | Jul 24, 2019 | clinicaltrials |
| NCT03202992 | Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection | completed | Phase 1 | 57 | Antiva BiosciencesINDUSTRY | 2 | Feb 7, 2019 | clinicaltrials |
| NCT01923116 | Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia(VACCAIN-T) | completed | Phase 1 / Phase 2 | 40 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Mar 15, 2018 | clinicaltrials |
| NCT02280811 | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2017 | clinicaltrials |
| NCT00654160 | Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 7 | Mayo ClinicOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01115790 | A Phase 1 Study in Participants With Advanced Cancer | completed | Phase 1 | 150 | Eli Lilly and CompanyINDUSTRY | 1 | May 10, 2016 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT00019110 | Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00066430 | Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia | completed | Phase 1 | 18 | AIDS Malignancy ConsortiumNETWORK | 1 | Sep 17, 2014 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
Data updated 4 days agoSource updated Sep 22, 2026source: clinicaltrials